Jonstam et al. determined that 16 weeks of dupilumab therapy significantly decreases the concentrations of PARC and eotaxin-2 and -3 in nasal secretions and homogenized nasal polyps [55]. This evidence concerns the gene CCL24 and nasal cavity polyp.